Investigation into Breach of Fiduciary Duty Claims concerning the Acquisition of Zoll Medical Corporation by Asahi Kasei Corporation announced by Leading National Securities Law Firm Gilman Law LLP.
The National Securities Law Firm Gilman Law LLP has launched a breach of fiduciary duty investigation into possible breach of fiduciary duty claims concerning current shareholders of Zoll Medical Corporation (“Zoll”) (NASDAQ: ZOLL) and other violations of state law by the board of directors of Zoll relating to the proposed acquisition of Zoll by Asahi Kasei Corporation (“Asahi”). Gilman Law’s breach of fiduciary duty investigation seeks to determine whether the board breached its fiduciary duties by failing to maximize shareholder value in negotiating the agreement to sell the company to Asahi.
On March 12, 2012, Zoll and Asahi announced that they had entered into a definitive agreement providing for Asahi to acquire Zoll for approximately $2.1 billion. Under the terms of the Zoll acquisition merger agreement, Zoll shareholders will receive $93.00 for each share of Zoll common stock held. However, according to news media, at least one analyst has set a high price target of $100.00 per share. The transaction is expected to close in the second calendar quarter of 2012.
If you currently own shares of Zoll and would like to learn more about the breach of fiduciary duty investigation by the National Securities Law Firm Gilman Law LLP, you may contact our office for a free consultation by calling (239) 221-8401 or by filling out our free consultation form online.
About The Leading National Securities Law Firm Gilman Law LLP
The leading national securities law attorneys at Gilman Law have over 35 years of experience litigating securities and other class action cases. Our firm has been involved in all major aspects of securities litigation, including cases involving stock manipulation, securities fraud, investment fraud, and shareholder rights violations, as well as securities class action suits on behalf of both individual and institutional investors.